Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus

  • 383 Accesses

  • 9 Citations

Abstract

Purpose

A grow body of studies has evaluated the risk of development of urological cancer in systemic lupus erythematosus (SLE) with inconclusive results. To clarify the association, a meta-analysis approach was performed to assess the published evidence on urological cancers and SLE.

Methods

Relevant English electronic databases were systematic searched for published studies characterizing the risk of developing urological cancer as a result of SLE. Standardized incidence rate (SIR) with its 95 % confidence interval (CI) of each study was combined using a fixed-/random-effect model in STATA software.

Results

A total of 12 papers including 68366 SLE patients were suitable for meta-analysis. Of these, 9 reported the SIR for prostate cancer, 7 for bladder cancer and 6 for kidney cancer. Summary SIRs were 0.77 (95 % CI 0.69–0.87, P < 0.001); 1.75 (95 % CI 0.94–3.23, P = 0.075) and 2.29 (95 % CI 1.25–4.18, P = 0.007), respectively. Significant heterogeneity was noticed in subgroups of bladder and kidney cancer. No obvious publication bias was detected.

Conclusions

Findings from this meta-analysis indicate that SLE is associated with a decreased risk of prostate cancer and an increased risk of kidney cancer.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39(6):1050–1054

  2. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

  3. Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE (2011) Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 104(9):1478–1481

  4. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M et al (2013) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130–135

  5. Björnådal L, Löfström B, Yin L, Lundberg IE, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31(2):66–71

  6. Cammarata RJ, Rodnan GP, Jensen WN (1963) Systemic rheumatic disease and malignant lymphoma. Arch Intern Med 111:330

  7. Chen YJ, Chang YT, Wang CB, Wu CY (2010) Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med 123(12):1150.e1-6

  8. Chun BC, Bae SC (2005) Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang lupus cohort in Seoul. Korea. Lupus. 14(8):635–638

  9. Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus. 10(6):394–400

  10. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

  11. Dreyer L, Faurschou M, Mogensen M, Jacobsen S (2011) High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term follow up study in a Danish cohort. Arthritis Rheum 63(10):3032–3037

  12. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

  13. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558

  14. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90

  15. Kang KY, Kim HO, Yoon HS, Lee J, Lee WC, Ko HJ et al (2010) Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 29(4):381–388

  16. Kinlen LJ (1992) Malignancy in autoimmune diseases. J Autoimmun 5(Suppl A):363–371

  17. Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799

  18. Liu H, Ding Q, Yang K, Zhang T, Li G, Wu G (2011) Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford) 50(2):343–348

  19. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

  20. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40(4):761–768

  21. Mok CC, Lau CS (2000) Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus 9(4):252–257

  22. Mononen N, Schleutker J (2009) Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. J Urol 181(4):1541–1549

  23. Ni J, Qiu LJ, Hu LF, Cen H, Zhang M, Wen PF et al (2014) Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. Lupus. doi:10.1177/0961203313520060

  24. Nived O, Bengtsson A, Jönsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10(7):500–504

  25. Parikh-Patel A, White RH, Allen M, Cress R (2008) Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 19(8):887–894

  26. Ragnarsson O, Gröndal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12(9):687–691

  27. Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 39(10):1147–1152

  28. Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G et al (2007) Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann N Y Acad Sci 1108:76–82

  29. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344

Download references

Conflict of interest

None.

Author information

Correspondence to Hou-bao Huang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Huang, H., Jiang, S., Han, J. et al. A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus. J Cancer Res Clin Oncol 140, 1067–1073 (2014). https://doi.org/10.1007/s00432-014-1604-8

Download citation

Keywords

  • Urological cancer
  • Systemic lupus erythematosus
  • Meta-analysis
  • SIR